Ribociclib FDA label updated to include pre- and perimenopausal women
  • Save
©United States Food and Drug Agency

FDA approved avatrombopag for thrombocytopenia in CLD patients scheduled for a procedure

/1 Comment/in /by

 

Ribociclib FDA label updated to include pre- and perimenopausal women
  • Save
You might also like
Ribociclib FDA label updated to include pre- and perimenopausal women
  • Save
©United States Food and Drug Agency FDA approved biosimilar pegfilgrastim to decrease the chance of febrile neutropenia in patients with non-myeloid cancers on myelosuppressive chemotherapy
  • Save
PD-1 mAB cemiplimab FDA approved for locally advanced and metastatic cutaneous squamous cell carcinoma (CSCC)
  • Save
Frontline atezolizumab plus bevacizumab and chemotherapy FDA approved for metastatic non-squamous NSCLC
More Information.  July 31, 2018.">
  • Save
More Information.  July 31, 2018." alt="FDA approved lusutrombopag (Mulpleta, Shionogi Inc.) for thrombocytopenia in adults with chronic liver disease who are scheduled to undergo a medical or dental procedure. More Information.  July 31, 2018." height="180" width="180" srcset="https://medi-paper.com/wp-content/uploads/2018/08/FDA-approved-lusutrombopag-Mulpleta-Shionogi-Inc.-for-thrombocytopenia-in-adults-with-chronic-liver-disease-who-are-scheduled-to-undergo-a-medical-or-dental-procedure.-More-Information.-July-31-2018-e1537925382959-180x180.jpg 180w, https://medi-paper.com/wp-content/uploads/2018/08/FDA-approved-lusutrombopag-Mulpleta-Shionogi-Inc.-for-thrombocytopenia-in-adults-with-chronic-liver-disease-who-are-scheduled-to-undergo-a-medical-or-dental-procedure.-More-Information.-July-31-2018-e1537925382959-80x80.jpg 80w, https://medi-paper.com/wp-content/uploads/2018/08/FDA-approved-lusutrombopag-Mulpleta-Shionogi-Inc.-for-thrombocytopenia-in-adults-with-chronic-liver-disease-who-are-scheduled-to-undergo-a-medical-or-dental-procedure.-More-Information.-July-31-2018-e1537925382959-36x36.jpg 36w, https://medi-paper.com/wp-content/uploads/2018/08/FDA-approved-lusutrombopag-Mulpleta-Shionogi-Inc.-for-thrombocytopenia-in-adults-with-chronic-liver-disease-who-are-scheduled-to-undergo-a-medical-or-dental-procedure.-More-Information.-July-31-2018-e1537925382959-120x120.jpg 120w, https://medi-paper.com/wp-content/uploads/2018/08/FDA-approved-lusutrombopag-Mulpleta-Shionogi-Inc.-for-thrombocytopenia-in-adults-with-chronic-liver-disease-who-are-scheduled-to-undergo-a-medical-or-dental-procedure.-More-Information.-July-31-2018-e1537925382959-450x450.jpg 450w" sizes="(max-width: 180px) 100vw, 180px"> Lusutrombopag FDA approved for thrombocytopenia in adult chronic liver disease patients
  • Save
Erdafitinib FDA approved for the treatment of metastatic urothelial carcinoma
Ribociclib FDA label updated to include pre- and perimenopausal women
  • Save
©United States Food and Drug Agency Ivosidenib FDA approved for relapsed or refractory acute myeloid leukemia
Ribociclib FDA label updated to include pre- and perimenopausal women
  • Save
©United States Food and Drug Agency FDA approves dabrafenib plus trametinib for anaplastic thyroid cancer with BRAF V600E mutation
  • Save
Trastuzumab-biosimilar Herzuma® FDA approved in HER2+ breast cancer
1 reply

Trackbacks & Pingbacks

  1. FDA approved avatrombopag for thrombocytopenia in CLD patient scheduled for a procedure - MediNews Asia says:
    23rd May 2018 at 11:47 PM

    […] post FDA approved avatrombopag for thrombocytopenia in CLD patient scheduled for a procedure appeared first on Medical Writer Agency | 香港醫學作家 | MediPR | MediPaper Hong […]

Leave a Reply

Want to join the discussion?
Feel free to contribute!

Leave a Reply